Immune profile in patients with sCAP and in healthy adults
sCAP
INFLAMMATORY DISEASE
Demographics and baseline characteristics of sCAP patients (CIGMA trial) and healthy subjects (phase I study) are presented in Table In the CIGMA trial, corticosteroid use was balanced between trimodulin and placebo groups with 61/81 (75%) and 64/79 (81%) exposed, respectively. The same was found for other drugs with immunomodulatory activity used to treat sCAP or any other underlying inflammatory disease (Additional file 